Market News

Lead asset THOR-707 being explored across multiple solid tumor types alone and in combination with immune checkpoint inhibitors and other future IO combinations.

Expansion increases capacity for the company's topical and transdermal services, as well as dedicated innovation, microbiology and histology laboratories.

Pharmapack 2020 gathering top specialists and pioneers to exchange their vision on best strategies to tackle key challenges.

New innovation has considerable potential to be used as a new environmentally friendly matrix for the microencapsulation and controlled release of a wide range of actives.

Lilly Gateway Labs will provide biotech companies direct access to Lilly scientists and expertise.

Unprecedented levels of investment cited as a major force driving the expansion.

The financial backing will help the company to develop a new generation of microbial air monitors that enables continuous monitoring as demanded by the Annex 1 revision.

ClearMixx performs liquid/liquid and powder/liquid mixing, with a dispersion plate able to efficiently mix the most challenging buffer, media and biopharmaceutical ingredients.

Content sessions identify value-added medicines, preventive drugs, early diagnostics and patient experience as some of the trends for the year ahead.

The largest area of growth has been within biotechnology companies, where job openings increased by 35%.

The company's diabetes nutrition drink, Celevida, is formulated to help manage blood glucose levels.

The rise in exports growth potential is believed to be in response to concerted reforms by the CDSCO and industry quality improvements in the last few years.

Company's multimillion euro investment will enable it to meet growing market demands from clients providing cancer treatments.

The new center will provide expertise in critical analytical processes and specialized workflows.

The device's blister is designed to provide flexibility to pharmaceutical partners delivering a wide range of inhaled drugs for both acute and chronic respiratory treatments.

The CDMO offers to acquire Consort Medical to become a Top Five global CDMO player.

Marks the latest step in the company’s ongoing efforts to engage with other organisations working to tackle antimicrobial resistance.

New models can help researchers investigate disease development and find new treatment approaches.

The device supports the new EU GMP Annex 1 requirements.

China-US trade challenges has led to de-risking by pharma companies.

Companies and individuals from across the whole pharma supply chain recognised for their excellence and commitment.

But personalized medicines will require new logistics and manufacturing systems.

Partnership will combine capabilities and expertise in Europe and India to build a new facility dedicated to injectable formulations to supply demand from Europe and overseas territories.

Demand for biological manufacturing is growing faster than capacity growth.

Company to reach 250 employees by year end to meet growing drug product manufacturing demand.

Company's strategic move reflects its expectation of short-run aseptic liquid filling to continue to drive pharmaceutical growth.

A shortage of qualified personnel may be a drag factor in cell and gene therapies; in China 100,00L of capacity will need to be added every year to meet bio demand.

Services including method development, method validation, and stability program design and implementation.

15,000 sq. ft of laboratory and office space will enable continued growth and development of the company’s integrated desktop platform for DNA synthesis.

Free webinar to discuss the benefits of a collaborative approach to implementing an electronic batch record platform.

CDMO to invest over €3 million in GMP facility expansion.

The investment will allow the CDMO to take on new projects, as well as bolster the company's chemistry development capabilities.

Germany establishes itself as Europe's leading pharma market in 2019.

Outsourcing, biologics, generics and patient compliance look set to get tongues wagging at this year's CPHI WW.

Highest level of data integrity as requested by regulatory authorities.

CPHI Worldwide's Annual Report suggests repeat offenders of regulatory infringements should be barred from importing into the US.

Leaders in atrial fibrillation and wearable technology to develop educational content around atrial fibrillation to help identify and support those at increased risk of stroke.

Experts to discuss innovative solutions to rare disease clinical trials.

The winners’ shortlist is packed with 40 of the industry’s most innovative companies and individuals who are shaping the future of pharma.

The approval of Eli Lilly's Reyvow represents the first new class of acute migraine treatment approved by the FDA in more than two decades.

One of the first digital manufacturing facilities in the world to use continuous, intensified biologics production technology.

Company's Ibex Design planned to take Genmab’s pre-clinical candidates from gene to potential IND within 12 months.

European financing to support Univercells’ R&D investments to develop four essential and undersupplied global health vaccines to be produced at affordable prices, high quality and large volumes.

Coordinated purification process development service accelerates progress to clinical trials, and scale-up manufacturing.

Innovative ART products now available in Europe.

Expansion creates 200 new full-time jobs and increases the company’s production capacity by an additional 19,100 m2.

A trifecta of relief formulated with HydroCell technology offers new artificial tear options for patients suffering from eye dryness.

Research aims to identify novel dermocosmetic active ingredients via unique microbiome-on-a-chip technology.

Market entrance with biotech-based natural vanillin, valencene and nootkatone.

In 2020, nutra brands will look to ensure they have plant-based options across all product classes with many actively looking to move entire portfolios plant-based.

Platform will enable scientists and biotechnology entrepreneurs worldwide to make discoveries faster and more efficiently,

The active ingredient is a 100% natural extract from the chaga mushroom, obtained using an innovative eco-friendly technology: subcritical water extraction.

Report predicts tomorrow’s biggest industry winners will need to invest now ahead of the curve.

Part of nearly $400 million in US manufacturing investments to deliver on the company’s pipeline and bring medicines to patients faster.

Plan in the kingdom is to raise the percentage of total pharmaceutical production to 40% from the current 20%.

E-commerce platform serves scientists by providing a wide selection of compounds from trusted worldwide suppliers for easy search, convenient ordering and hassle-free delivery.

Epidyolex (cannabidiol) approved for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy.

New drug works like a ‘magic bullet’ that is delivered directly to the mitochondria of cancer cells.

An increasing number of AI algorithms are now approved by the US Government – a trend that is set to continue as understanding of AI matures.

Event sees new Memorandum of Understanding signed by PROLMED and KPTA.

The fund will target investments in transformational solutions across manufacturing, supply chain, and delivery of pharmaceutical products and services.

To support its strong growth, M2i Life Sciences has concluded a capital increase of 60 million Euros with five leading investors (ADM Capital, Eurazeo Growth, Téthys Invest, Creadev and France 2i fund managed by RAISE Impact).

New formulation of oxycodone hydrochloride contains the narcotic antagonist naloxone in order to prevent abuse.

Transaction continues to advance Mallinckrodt's strategic focus on branded, high-growth biopharmaceuticals by monetizing a non-core business.

Delivers enhanced galactosylation for improved protein quality, and antibody binding and function.

Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth.

Use your voice to shape CPHI Worldwide's third annual global survey of the major trends, changes and developments in the industry.

Maxwellia considered to have the skills and the expertise to deliver and reach their goal of creating the big OTC brands of the future.

Company's new building in Wixom, MI replace and consolidate its existing manufacturing site in Kalamazoo, MI.

The test can accurately predict the risk of having metastases present in the lymph nodes without having to undergo surgery to remove lymph nodes.

The potential for generics to support the healthcare needs of China is significant.

Customers claim Bora's oral solid dosage Zhunan facility is in the top 5 external manufacturing facilities they’ve ever visited in the world.

Worldwide agreement with Polpharma gives Sandoz commercialization rights to proposed biosimilar natalizumab for relapsing-remitting multiple sclerosis.

The collaborative project will develop and explore new formulation possibilities using softpellets and nanocrystals for high dose administration via dry powder inhalation using antibiotics such as clarithromycin and rifampicin as model drugs.

New data shows pharmaceutical-quality lavender oil significantly improves anxiety-induced insomnia when taken as a daily capsule.

Atelerix Consortium awarded £267,000 Innovate UK Grant for collaboration with the Cell and Gene Therapy Catapult and Rexgenero on cell therapy stabilisation technologies.

Using Nanologica's technology, Sterling will produce the large volumes of NLAB Saga chromatography material needed by Yunbo Technology to perform preparative chromatography.

Alvotech Contract Services will be responsible for commercial production using its new state-of-the-art biosimilar facility in Reykjavik, Iceland.

New offices at leading science hub support the company’s rapid growth following recent investment.

Company acquires leading immunology drug Otezla from Celgene for $13.4 billion.

Company provided FDA investigators with multiple documents that were falsified.

Successful transformation to paperless factory brings huge benefits in quality, regulatory compliance, operations and data availability.

Company's antibody screening platform minimizes the risk of missing a blockbuster.

The longest, highest fidelity, and ready-to-use custom oligo pools on the market.

Pipeline of new drugs has helped drive increased innovation in packaging and drug delivery devices.

The five-level production facility contains a state-of-the-art manufacturing line for viral vaccines and viral vectors and a separate protein manufacturing area with a capacity up to 1,000-L single-use bioreactors.

Bringing freeze drying and vial washing/sterilizing technologies together with advanced and comprehensive vial and syringe filling capabilities.

Company acquires unit-dose nasal and sublingual spray manufacturing equipment, as well as two pipeline products.

Utilising the current data environment and its data pools for the benefit of advancing research.

Researchers study how radiofrequency electromagnetic fields could be used in Alzheimer’s disease therapy.

Integrated package of new and established services saves time and minimizes risks.

The CDMO's shareholders will receive $60.00 per share in cash.

The benefits of this innovation include the ability to instantly and unequivocally authenticate products when suspect events.

Group aiming to achieve a 50% reduction in absolute GHG emissions based on 2006 levels by 2030 and an 80% reduction by 2050.

Opportunities abound at CPHI MEA and experts anticipate regional generic companies acting as CMOs for international companies looking to enter the region.

Represents the first non-invasive diagnostic tool capable of providing a profile of microbiome populations throughout the entire GI tract.

Fluidity One-W wins SLAS new product award for enabling in-solution interaction analysis of challenging proteins.

The news business will manufacture chemical ingredients that can be used in the development of drug products, and in the healthcare and cosmetics industries.

Korean companies are opening more facilities overseas and using CPHI Korea to look for new international partners.

The transaction will allow the new company to expand the geographic reach of Mylan's existing broad product portfolio and future pipeline.

Aptar’s nasal Unidose device - the result of a 10-year customer collaboration - marks the first FDA approval of a prescription drug using the company’s patented Unidose Powder System.

Company also announces approval of third commercial ADC.

New agreement allows MedPharm to react quickly to changes in requirements and makes full use of its comprehensive services for de-risking Novan’s product development.

Under the agreement, Hikma will produce 14 essential sterile injectable medications for Civica.

Great Hall of China: Informa adds additional capacity to Asia’s largest pharma event with record 66,000+ visits from 141 countries.

The company will provide expertise in next-generation biomolecule purification processes and long-term supply of CIMmultus monolithic columns.

By 2020, all medicines imported into and traded within Russia must comply with Russian Federal Law No. 425-FZ.

Company to install new inspection cameras with higher resolution to ensure readability of more complex codes demanded by the Russian mandated crypto coding.

The AF4-MALS-RI method makes possible the accurate determination of molecular weight distribution of polysaccharide macromolecules.

CVC Capital Partners to " take the business forward in the years ahead, and to make it even more competitive".

The new brand - Lubrizol Life Sciences - aims to maximize client speed-to-market, providing enhanced solutions.

The GMP facility has been specifically designed to deliver the next generation of anticancer blockbuster ADC drugs for patients globally.

The plant will provide a secure second source of supply of Starch 1500, Pregelatinized Maize Starch.

Opening of continuous manufacturing facilities and expansion of production building will boost capabilities to accelerate the supply of new breakthrough medicines to patients globally.

Investment fills the growing gap in the market for manufacturers that have the niche capabilities to deliver small-scale commercial API projects.

It is hoped that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors.

Company's customers to have immediate access to Niro PSD2 and PSD4 spray driers, which are supported by dedicated clean area facilities for both solvent and aqueous processing of potent or non-potent drug formulations.

Proper maintenance - rather than replacement - of compression tooling will improve profitability.

The new facility houses 11 bespoke production suites and temperature controlled high-way warehouses increases Wasdell’s capacity in clinical and commercial packaging, distribution & logistics and QP services.

Offers a single optimised Chromatrap kit with unique buffers and components for Drosophila chromatin extraction and ChIP.